NCT06250543View on ClinicalTrials.gov

Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

November 25, 2022

Study Completion Date

November 25, 2022

Conditions
Overactive Bladder
Interventions
DRUG

AbobotulinumtoxinA 300 UNT

20 evenly distributed intradetrusor injections, 1 ml per site, were performed

DRUG

IncobotulinumtoxinA 100 UNT

20 evenly distributed intradetrusor injections, 1 ml per site, were performed

DRUG

Lidocain

30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter

OTHER

placebo

30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution

Trial Locations (1)

2000

University Medical Centre Maribor, Maribor

All Listed Sponsors
lead

Niko Kavcic

OTHER

NCT06250543 - Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder | Biotech Hunter | Biotech Hunter